



## Effects of QZ-16 on blood glucose and lipids in Streptozotocin induced diabetic rats

Abul K Najmi<sup>1,\*</sup>, KK Pillai<sup>1</sup>, Aftab Ahmad<sup>1</sup> and M Aqil<sup>2</sup>

<sup>1</sup>Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi-110 062, India; <sup>2</sup>Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi-110 062, India

### SUMMARY

The present study was designed to investigate the hypoglycaemic and hypolipidaemic activities of Qurs-e-Ziabetus 16 (QZ-16) in Streptozotocin (STZ) induced diabetic rats. QZ-16, a polypharmaceutical herbomineral formulation developed on the principles of Unani medicine is used for non-insulin dependent diabetes mellitus (NIDDM). The elevated levels of fasting blood glucose, serum levels of cholesterol, triglycerides and urea observed in rats treated with STZ (55 mg/kg body wt.) were significantly reduced by the treatment of QZ-16 (240 mg/kg, p.o.) and gliclazide (30 mg/kg, p.o.). The reduced HDL cholesterol levels were also increased by the QZ-16 and gliclazide treatments in the STZ induced diabetic rats. These data show that QZ-16 has hypoglycaemic, hypolipidaemic properties in STZ induced diabetic rats.

**Key words:** Qurs-e-Ziabetus 16; Unani medicine; Hypoglycaemia; Hypolipidaemia; Streptozotocin

### INTRODUCTION

QZ-16 is a polypharmaceutical herbomineral formulation containing five herbal ingredients namely *Azadirachta indica* A. Juss (Family: Meliaceae) (Leaves), *Gossypium herbaceum* Linn. (Family: Malvaceae) (Seeds), *Gymnema sylvestre* R.Br. (Family: Asclepiadaceae) (Leaves), *Rosa damascena* Mill (Family: Rosaceae) (Petals), *Syzygium cumini* (Linn) Skeels. (Family: myrtaceae) (seeds) along with two Kushtas, Kushta Hartal (Preparation: 25 g of Hartal is ground in 125 g of extract of *Calotropis gigantea* (Linn) R. Br. Cakes of the mass are then wrapped in the leaves of *Ricinus communis* linn and then heated for three hours after

putting in the ash of leaves of *Ficus religiosa* Linn. After cooling it to room temp Kushta Hartal is obtained) (Rafiquddin, 1980) and Kushta Baiza-e-Murgh (Preparation: 100 g of post-e-baiza-e-murgh (shell of hen's egg) is soaked in sufficient quantity of Aab-e-lemu (lemon extract) in a porcelain pot till dried. It is then kept in earthen discs sealed with a process of Gil-e-hikmat & subjected to a fire of 70×70×70 cm pit. The process is repeated twice) (National Formulary, 1983). This formulation is used by Unani physicians in the management of NIDDM (Vohora, 1983).

A preliminary study with QZ-16 in our laboratory showed the reduction of blood glucose and food intake and enhanced oral glucose tolerance in neonatally STZ induced diabetes in rats (Najmi *et al.*, 1999).

The present investigation is designed to present an experimental evidence that treatment with QZ-

\*Correspondence: Abul K Najmi, Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi-110 062, India. Tel: +91-11-26059686 ext. 5658; Fax: +91-11-26059663; E-mail: aknajmi@jamiahamdard.ac.in; aknajmi@hotmail.com

16 can result in reduction in the degree of hyperlipidaemia along with the reduction in the blood glucose in experimental diabetes.

## MATERIALS AND METHODS

### Drugs and chemicals

QZ-16, was provided by Hamdard (wakf) Labs. Ghaziabad, India. STZ was purchased from Sigma, USA. Gliclazide was purchased from Serdia, Mumbai, India. All the biochemicals and chemicals used were of analytical grade.

### Animals

Albino rats of Wistar strain weighing 100 - 150 g were used for the study. Animals were supplied by central Animal House facility of Hamdard University and kept under standard laboratory conditions in 12 h light/dark cycle at  $25 \pm 2^\circ\text{C}$ . Animals were supplied with pellet diet (Lipton, India) and water ad libitum.

### Experimental protocol

Fasting blood glucose levels of all the animals were determined and then divided into two groups. In group A, 10 animals were administered citrate buffer of pH 4.5 by tail vein. The animals in group B were administered STZ 55 mg/kg i.v. after dissolving in 0.1 M citrate buffer pH 4.5 after an overnight fast (Cam *et al.*, 1993). After 5 days period the fasting blood glucose level was determined for all the animals and 5 rats were randomly selected from group A showing normal glucose levels and were included in group I. From group B rats showing fasting blood glucose levels more than 250 mg/dl (Patel *et al.*, 1997) were selected and randomly divided into three groups II, III and IV each containing 6 rats (Ignacimuthu *et al.*, 1998).

Group I (Vehicle treated) served as normal control and received normal saline twice daily. Animals in group II (STZ- treated) served as toxic control and received normal saline 1 ml/kg p.o twice daily. Rats in group III (STZ treated) received

QZ-16 (240 mg/kg p.o) twice daily. Rats in group IV (STZ treated) received gliclazide (30 mg/kg p.o) twice daily.

Treatment was continued for a period of 30 days and on 31<sup>st</sup> day the blood was collected from retro orbital plexus under light ether anesthesia for estimation of various biochemicals. The blood samples were allowed to clot for 30 - 40 min. serum was separated by centrifugation at  $37^\circ\text{C}$  and was used for biochemical estimation.

### Biochemical estimations

Biochemical parameters blood glucose (Brahm and Trinder., 1972), serum total cholesterol (Warnick *et al.*, 1985), serum triglycerides (Fossati *et al.*, 1982), HDL Cholesterol (Demacher *et al.*, 1980; Warnick *et al.*, 1985), serum urea (Teitz, 1976) were analyzed according to the reported procedures.

### Statistical analysis

Results are expressed as mean  $\pm$  SEM. The significance of difference was assessed by using students 't' test and ANOVA. F ratio was also calculated. *P* values < 0.05 were regarded as significant.

## RESULTS

A significant increase in the fasting blood glucose levels was observed in the STZ treated animals (group II, III and IV) as compared with citrate buffer treated animals (group I). Treatment of STZ challenged animals (group II, III & IV) by QZ-16 (240 mg/kg p.o) and gliclazide (30 mg/kg p.o) twice daily for 30 days respectively brought about significant reduction in the fasting blood glucose levels as compared with the fasting blood glucose levels in these animals before treatment with QZ-16 and gliclazide and also with STZ challenged animals treated with normal saline (1 ml/kg p.o) twice daily for 30 days (group II) (Table 1).

Levels of serum cholesterol, triglycerides and urea increased by STZ treatment were decreased significantly by the treatment of rats with QZ-16

**Table 1.** Effect of QZ-16 and gliclazide on fasting blood glucose levels in control and streptozotocin induced diabetic rat

Group	Blood glucose conc. mg/dl	
	Before Treatment	After Treatment
I	107.72 ± 2.71	112.01 ± 2.88 <sup>ns</sup>
II	322.11 ± 12.10	332.44 ± 13.42 <sup>ns</sup>
III	328.25 ± 14.64	184.35 ± 16.40 <sup>**</sup>
IV	332.89 ± 14.37	179.11 ± 14.22 <sup>**</sup>

Values represents ± SEM (group I, n = 5, group II, n = 6). After treatment values are compared with before treatment values by paired 't' test. \*\*P < 0.01, <sup>ns</sup> = not significant.

(240 mg/kg p.o) and gliclazide (30 mg/kg p.o) twice daily for 30 days, Moreover the significant decrease in the HDL cholesterol observed in animals treated with STZ (group II) as compared with normal control group (group I) was also increased by QZ -16 and gliclazide treatments (Table 2).

## DISCUSSION

STZ injection in rats causes hyperglycaemia, hypercholesterolemia, hypertriglyceridemia, increased serum urea conc. etc. (Silva et al., 2001; Umrani et al., 2002). Glucose lowering effect of QZ-16 may possibly be due to the presence of *Azadirachta indica*, *Gossypium herbaceum*, *Gymnema sylvestre*, *Syzigium cumini*, and Kushta Hartal (Rizvi and Rizvi, 1987; AttaurRehman and Zaman, 1989; Handa et al., 1989; Bopanna et al., 1997; Sugihara et al., 2000). Decoction of leaves of *Azadirachta indica* has been

shown to possess antidiabetic activity. Nimbidin a constituent of this plant significantly delays the peak rise in blood sugar after glucose administration (Bopanna et al., 1997). The leaves extract (500 mg/kg B. wt.) and seed oil (5 ml/kg b. wt.) of *Azadirachta indica* have been reported to decrease glycaemia in alloxan diabetic rabbits (Khosla et al., 2000). *Gymnema sylvestre* contains gymnemic acid which acts by increasing insulin release from β-cells of langerhan's (Shanmugasundaram et al., 1981; Persaud et al., 1999), and glycogen synthetase (Shanmugasundaram et al., 1983). Hexokinase catalyses the entry of glucose in to alternative metabolic pathways and glycogen synthetase is responsible for control of glycogen metabolism. Besides this it can abolish the sensations of sweet and bitter taste (Bailey and Caroline, 1989; Ye et al., 2001). It also causes suppression of glucose absorption by inhibiting glucose uptake in the intestine (Shimizu et al., 1997). In a clinical study leaf extract of *Gymnema sylvestre* was found to produce significant reduction in blood glucose, glycosylated hemoglobin and glycosylated plasma proteins (Baskaran et al., 1990). Epinephrin induced hyperglycaemia was also antagonized by *Gymnema sylvestre* (Gupta and Variyar, 1961). Seeds of *Syzigium cumini* contains glycoside jumboline which prevents the conversion of starch into sugar (Nadkarni, 1979). Oral administration of aqueous extract (2.5 ml/kg B. wt.) of the seeds has been shown to significantly reduce the blood glucose and increase total hemoglobin content (Prince et al., 1998).

The aqueous extract (2.5 ml/kg B. wt.) of

**Table 2.** Effect of QZ-16 and gliclazide on serum lipid and urea levels in control and streptozotocin induced diabetic rats (mg/dl)

Group	Triglycerides	Cholesterol	HDL Cholesterol	Urea
I	76.54 ± 4.04	77.41 ± 1.53	43.64 ± 0.75	35.96 ± 1.52
II	173.66 ± 11.61 <sup>**</sup>	129.49 ± 3.83 <sup>***</sup>	28.47 ± 1.78 <sup>**</sup>	97.99 ± 1.40 <sup>***</sup>
III	57.28 ± 7.94 <sup>**</sup>	75.44 ± 5.96 <sup>**</sup>	37.18 ± 2.07 <sup>*</sup>	50.63 ± 2.86 <sup>***</sup>
IV	80.36 ± 9.90 <sup>**</sup>	85.54 ± 3.56 <sup>**</sup>	38.39 ± 3.02 <sup>*</sup>	41.55 ± 4.26 <sup>***</sup>
F-ratio	34.99 <sup>#</sup>	39.68 <sup>#</sup>	9.81 <sup>#</sup>	103.25 <sup>#</sup>

Values represent ± SEM, (group I, n = 5, group II, n = 6). Group II is compared with group I and groups III & IV are compared with group II. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001; #P < 0.005

*Syzigium cumini* results in the decreased free radical formation in the tissues studied (Prince *et al.*, 1998). *Azadirachta indica* (Arivazhagan *et al.*, 2000) and *Rosa damascena* (Bolwell *et al.*, 1998) have also been shown to possess antioxidant property. It has been reported that in diabetes, plasma lipid peroxide levels are increased, it has also been shown that increased plasma lipid peroxidations are accompanied by the depression of glutathione-dependent antioxidant defense mechanism of the body (Uzel *et al.*, 1987; Baydas *et al.*, 2002). Several other investigators have also reported that increased oxidative stress plays an important role in the pathogenesis of diabetes mellitus (Maxwell *et al.*, 1997; Desco *et al.*, 2002; Zobali *et al.*, 2002). Hence it can be hypothesized that antioxidant property of *Azadirachta indica*, *Rosa damascena* and *Syzigium cumini* may also contribute in the overall improvement in diabetic state of the rats in the present study.

Kushta Hartal has been shown to produce hypoglycaemia significantly and reduce other diabetic symptoms in a clinical study (Rizvi and Rizvi, 1987). Although Kushta Baiza Murgh is used in diabetes in unani medicine but no clinical or experimental reports are available about its efficiency (Vohora, 1990).

Abnormalities of fat metabolism are also accelerated in diabetes mellitus. The manifestations of disordered lipid metabolism are so prominent that diabetes has been called more a disease of lipid than that of carbohydrate metabolism (Ganong, 1991). Elevated level of serum total cholesterol, and triglycerides were found in the STZ diabetic rats (Umrani *et al.*, 2002), these are increased in diabetic patients also (Zargar *et al.*, 1997). Rise in cholesterol may be due to increase in plasma concentration of VLDL and LDL which may be due to increased hepatic production of VLDL and decreased removal of VLDL and LDL from circulation (Ganong, 1991), because of decreased activity of insulin dependent lipoproteins lipase (Stephen *et al.*, 1996).

*Azadirachta indica* (Bopanna *et al.*, 1997; Khosla *et al.*, 2000) and *Gymnema sylvestre* (Murshed *et al.*,

1996; Bhandari *et al.*, 1998; Shigematsu *et al.*, 2001) which are constituents of QZ-16, have been reported to possess hypolipidaemic and hypoglycaemic properties.

QZ-16 and gliclazide treatment significantly reduced the serum conc. of triglycerides, total cholesterol, which might be due to the improvement of the glucose tolerance (Najmi *et al.*, 1999). The elevated levels of HDL cholesterol concentration observed in QZ-16 and gliclazide treatment rats might be due to the influence of these drugs on carbohydrate and related metabolism.

STZ is known to produce nephrotoxicity by increasing the generation of free radicals (Mukhopadhyay, 1995; Degenhardt *et al.*, 2002) in the renal cells. The oxidative stress might be responsible for elevated urea level. Sustained hyperglycaemia also produces impairment of renal function (Pickup and Milan, 1990; Umrani *et al.*, 2002). Since QZ-16 contains antioxidant and hypoglycaemic principles. The reduction in serum urea might be due to the antioxidant and hypoglycaemic mechanisms.

#### ACKNOWLEDGEMENTS

Authors are thankful to Hamdard (Wakf) Labs. Ghaziabad for providing generous gift sample of Qurs-e-Ziabetus 16.

#### REFERENCES

- Arivazhagan S, Balasenthil S, Nagini S. (2000) Garlic and neem extracts enhance glutathione and glutathione dependent enzymes during MNNG induced gastric carcinogenesis in rats. *Phytother. Res.* **14**, 291-293.
- AttaurRehman, Zaman K. (1989) Medicinal plants with hypoglycaemic activity. *J. Ethnopharmacol.* **26**, 1-55.
- Bailey CJ, Caroline D. (1989) Traditional plant medicines as treatment for diabetes. *Diab. Care* **12**, 553-564.
- Baskaran K, Ahamath AB, Shanmugasundaram RK, Shanmugasundaram ER. (1990) Anti diabetic effect of a leaf extract from *Gymnema sylvestre* in non-insulin dependent diabetes mellitus patients. *J.*

- Ethnopharmacol.* **30**, 295-300.
- Baydas G, Canatan H, Turkoglu A. (2002) Comparative analysis of the protective effects of melatonin and vitamin E on streptozotocin induced diabetes mellitus. *J. Pineal Res.* **32**, 225-230.
- Bhandari U, Grover JK. (1998) A reappraisal of clinical studies on the comparative influence of three indigenous plant drugs in diabetes mellitus. *Hamdard Medicus* **XLI**, 9-15.
- Bolwell GP, Davies DR, Gerrish C, Auh CK, Murphy TM. (1998) Comparative biochemistry of the oxidative burst produced by rose and French bean cells reveals two distinct mechanisms. *Plant Physiol.* **116**, 1379-1385.
- Bombolkar S, Sainani GS. (1995) Evaluation of oxidative stress in diabetes with or without vascular complications. *J. Assoc. Physicians India* **43**, 10-12.
- Bopanna KN, Kannan J, Sushma G, Balaram R, Rathod SP. (1997) Antidiabetic and antihyperlipidaemic effects of neem seed kernel powder on alloxan induced diabetic rabbits. *Indian J. Pharmacol.* **29**, 162-167.
- Braham D, Trinder P. (1972) An improved colour reagent for the determination of blood glucose by the oxidase method. *Analyst* **97**, 142-145.
- Cam MC, Cros GH, Serrano JJ, Lazarok McNeil JH. (1993) In-vivo antidiabetic action of naglivan, an organic vanadyl compound in STZ-induced diabetes. *Diabetes Res. Clin. Pr.* **20**, 111-121.
- Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basken JM, Steffes MW. (2002) Pyrodoxamine inhibits early renal disease and dyslipidaemia in the STZ-diabetic rat. *Kidney Int.* **61**, 939-950.
- Demacher PNM, Hijmaus AGM. (1980) A study of the use of polyethylene glycol in estimating cholesterol. *Clin. Chem.* **26**, 1775-1776.
- Desco MC, Asensi M, Marquez R, Martinez-Valls J, Vento M, Pallardo FV, Sastre J, Vina J. (2002) Xanthine oxidase is involved in free radical production in diabetes: protection by allopurinol. *Diabetes* **51**, 1118-1124.
- Fossati P, Prencipe L. (1982) Triglyceride estimations. *Clin. Chem.* **28**, 2077.
- Ganong F. (1991) *Review of Medical Physiology*, pp.318, 15<sup>th</sup> ed., Prentice Hall (UK), London.
- Gupta SS, Variyar MC. (1961) Inhibitory effects of *Gymnema sylvestre* on adreno hypophysial activity in rats. *Indian J. Med. Sci.* **15**, 656-659.
- Handa SS, Chawla AS, Maninder. (1989) Hypoglycaemic plants- A review. *Fitoterapia* **60**, 195-223.
- Ignacimuthu S, Amalraj T. (1998) Effect of leaf extract of *Zizyphus jujuba* on diabetic rats. *Indian J. Pharmacol.* **30**, 107-108.
- Khosla P, Bhanwra S, Singh J, Seth S, Srivastava RK. (2000) A study of hypoglycaemic effects of *Azadirachta indica* (neem) in normal and alloxan diabetic rabbits. *Indian J. Physiol. Pharmacol.* **44**, 69-74.
- Maxwell SR, Thomson H, Sandler D, Leguen C, Baxter MA, Thorpe GH. (1997) Anti-oxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. *Eur. J. Clin. Invest.* **27**, 484-490.
- Mukhopadhyay S. (1995) Free radicals and diabetes- role in etiology and pathogenesis. *J. Diab. Assoc. India* **34**, 5-7.
- Murshed S, Sarkar S, Rokeya B, Banik NG, Ali L, Azad AK. (1996) Effects of *Gymnema sylvestre* and *Memordica charantia* on serum lipid levels of IDDM and NIDDM model rats. *Diabetologia* **39**, 236.
- Nadkarni KM. (1979) *Indian Materia Medica*, pp. 516-595, Vol. I, Bombay Popular Parkashan, Bombay.
- Najmi AK, Shah S, Bhandari U, Pillai KK. (1999) Effect of Qurs-e-Ziabetus 16 in neonatally streptozotocin induced diabetic rats. *Indian J. Pharmacol.* **31**, 237.
- National Formulary of Unani Medicine. (1983) pp. 69, Part I, First Ed., Department of health, Ministry of health and family welfare, Govt. of India.
- Patel KP, Zhang PL, Zeigler W, Kaukar ML. (1997) Renal response to volume expansion in STZ induced diabetes. *Diabetes Res. Clin. Pr.* **35**, 69-74.
- Persaud SJ, Al-Majed H, Raman A, Jones PM. (1999) *Gymnema sylvestre* stimulates insulin release in vitro by increased membrane permeability. *J. Endocrinol.* **163**, 207-212.
- Pickup J, Milan G. (1990). *Text Book of Diabetes*. pp. 25, Vol. I. Blackwell Publications, London.
- Prince PS, Menon VP, Pari L. (1998) Hypoglycaemic activity of *Syzygium cumini* seeds: effect on lipid peroxidation in alloxan diabetic rats. *J. Ethnopharmacol.* **61**, 1-7.
- Rafiquddin M. (1980) *Minhaj-us-saidla-wal-keemiya* (Urdu), pp.214-215, Publication Division, Aligarh Muslim University, Aligarh.
- Rizvi SNA, Rizvi SSA. (1987) Comparative clinical evaluation of the effectiveness and tolerability of a

- new Unani oral hypoglycaemic agent- Kushta Hartal and chlorpropamide in the treatment of maturity onset diabetes mellitus. First International Seminar on Unani Medicine, WHO, Delhi, Abstracts, p. 30.
- Shanmugasundaram KR, Panneerselvam C, Samudram P, Shanmugasundaram ERB. (1983) Enzyme changes and glucose utilization in diabetic rabbits: the effect of *Gymnema sylvestre* R. Br. *J. Ethnopharmacol.* **7**, 205-234.
- Shanmugasundaram KR, Panneerselvam C, Samudram P, Shanmugasundaram ER. (1981) The insulinotropic activity of *Gymnema sylvestre* R.Br., an Indian medical herb used in controlling diabetes mellitus. *Pharmacol. Res. Comm.* **13**, 475-486.
- Shigematsu N, Asano R, Shimosaka M, Okazaki M. (2001) Effect of long term administration with *Gymnema sylvestre* R. Br. on plasma liver lipid in rats. *Biol. Pharm. Bull.* **24**, 643-649.
- Shimizu K, Lino A, Nakajima J, Tanaka K, Nakajyo S, Urukawa N. (1997) Suppression of glucose absorption by some fractions extracted from *Gymnema sylvestre* leaves. *J. Vet. Med. Sci.* **59**, 245-251.
- Silva RM, Santos FA, Rao VS, Maciel MA, Pinto AC. (2001) Blood glucose and triglyceride lowering effect of trans-dehydrocrotonin, a diterpene from *Croton cajucara* Benth., in rats. *Diab. Obesity Metab.* **3**, 452-456.
- Stephen N, Granner DK. (1996) Oral hypoglycaemic agents and the pharmacology of endocrine pancreas. In: *Goodman's and Gilman's The pharmacological basis of therapeutics*, Edited by Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, pp. 1487-1519. 9<sup>th</sup> ed, Mc Grawhill, New York.
- Sugihara Y, Nojima H, Matsuda H, Murakami T, Yoshikawa M, Kimura T. (2000) Antihyperglycaemic effects of gymnemic acid IV, a compound derived from *Gymnema sylvestre* leaves in streptozotocin-diabetic mice. *J. Asian Nat. Products Res.* **2**, 321-327.
- Teitz NW. (1976) *Clinical Guide to Laboratory Tests*, pp.238, W.B. Saunders Co., Philadelphia.
- Umrani DN, Goyal RK. (2002) Beneficial effects of fenoldopam treatment on renal function in streptozotocin-induced diabetic rats. *Clin. Exp. Hypertens.* **24**, 207-219.
- Uzel N, Sivas A, Uysal M, Oz H. (1987) Erythrocyte lipid peroxidation and glutathione peroxidase activities in patients with diabetes mellitus. *Horm. Metab. Res.* **19**, 89-90.
- Vohora SB. (1990) Elementology of diabetes mellitus. *Am. J. Chinese Med.* **18**, 131-138.
- Vohora SB. (1983) *Medical Elementology*, pp.43-51, Institute of Medicine and Medical Research, Hamdard Nagar, New Delhi, India.
- Warnick GR, Nguyen T, Albers AA. (1985) Comparison of improved method for quantification of HDL cholesterol. *Clin. Chem.* **31**, 217.
- Ye W, Liu X, Zhang Q, Che CT, Zhao S. (2001) Antisweet saponins from *Gymnema sylvestre*. *J. Nat. Prod.* **64**, 232-235.
- Zargar AM, Majaaz BM, Masoodi SR, Laway BA, Dar FA. (1997) Serum cholesterol triglycerides and total lipids in well controlled non insulin dependent diabetes mellitus. *J. Diab. Assoc. India* **37**, 37-40.
- Zobali F, Besler T, Ari N, Karasu C. (2002) Hydrogen peroxide induced inhibition of vasomotor activity: evaluation of single and combined treatments with vitamin A and insulin in streptozotocin diabetic rats. *Int. J. Exp. Diab. Res.* **3**, 119-130.